Stem Cell Authority, Ltd.
Stem Cell Authority, Ltd. (SCAL) Stock Competitors & Peer Comparison
See (SCAL) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SCAL | $0.00 | +0.00% | 17.4K | 0.04 | $0.01 | N/A |
| FSNUY | $12.72 | +1.17% | 114.7B | 16.11 | $0.79 | +2.22% |
| FSNUF | $57.00 | +4.88% | 32.1B | 18.10 | $3.15 | +1.99% |
| JDHIY | $7.00 | +2.19% | 22.4B | 29.17 | $0.24 | N/A |
| JDHIF | $6.15 | +0.00% | 19.7B | 29.29 | $0.21 | N/A |
| FMCQF | $44.25 | -10.08% | 12.4B | 15.26 | $2.90 | +3.67% |
| BDULF | $0.66 | +0.00% | 10.5B | 22.00 | $0.03 | +4.59% |
| BDUUY | $25.24 | +23.60% | 10B | 20.69 | $1.22 | +3.75% |
| IHHHF | $1.10 | -24.14% | 9.7B | 15.71 | $0.07 | +2.33% |
| BDUUF | $0.60 | -7.69% | 9.5B | 20.00 | $0.03 | +5.05% |
Stock Comparison
SCAL vs FSNUY Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, FSNUY has a market cap of 114.7B. Regarding current trading prices, SCAL is priced at $0.00, while FSNUY trades at $12.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas FSNUY's P/E ratio is 16.11. In terms of profitability, SCAL's ROE is +0.07%, compared to FSNUY's ROE of +0.07%. Regarding short-term risk, SCAL is less volatile compared to FSNUY. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check FSNUY's competition here
SCAL vs FSNUF Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, FSNUF has a market cap of 32.1B. Regarding current trading prices, SCAL is priced at $0.00, while FSNUF trades at $57.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas FSNUF's P/E ratio is 18.10. In terms of profitability, SCAL's ROE is +0.07%, compared to FSNUF's ROE of +0.07%. Regarding short-term risk, SCAL and FSNUF have similar daily volatility (0.00).Check FSNUF's competition here
SCAL vs JDHIY Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, JDHIY has a market cap of 22.4B. Regarding current trading prices, SCAL is priced at $0.00, while JDHIY trades at $7.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas JDHIY's P/E ratio is 29.17. In terms of profitability, SCAL's ROE is +0.07%, compared to JDHIY's ROE of +0.09%. Regarding short-term risk, SCAL is less volatile compared to JDHIY. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check JDHIY's competition here
SCAL vs JDHIF Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, JDHIF has a market cap of 19.7B. Regarding current trading prices, SCAL is priced at $0.00, while JDHIF trades at $6.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas JDHIF's P/E ratio is 29.29. In terms of profitability, SCAL's ROE is +0.07%, compared to JDHIF's ROE of +0.09%. Regarding short-term risk, SCAL and JDHIF have similar daily volatility (0.00).Check JDHIF's competition here
SCAL vs FMCQF Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, FMCQF has a market cap of 12.4B. Regarding current trading prices, SCAL is priced at $0.00, while FMCQF trades at $44.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas FMCQF's P/E ratio is 15.26. In terms of profitability, SCAL's ROE is +0.07%, compared to FMCQF's ROE of +0.07%. Regarding short-term risk, SCAL and FMCQF have similar daily volatility (0.00).Check FMCQF's competition here
SCAL vs BDULF Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, BDULF has a market cap of 10.5B. Regarding current trading prices, SCAL is priced at $0.00, while BDULF trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas BDULF's P/E ratio is 22.00. In terms of profitability, SCAL's ROE is +0.07%, compared to BDULF's ROE of +0.15%. Regarding short-term risk, SCAL and BDULF have similar daily volatility (0.00).Check BDULF's competition here
SCAL vs BDUUY Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, BDUUY has a market cap of 10B. Regarding current trading prices, SCAL is priced at $0.00, while BDUUY trades at $25.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas BDUUY's P/E ratio is 20.69. In terms of profitability, SCAL's ROE is +0.07%, compared to BDUUY's ROE of +0.15%. Regarding short-term risk, SCAL and BDUUY have similar daily volatility (0.00).Check BDUUY's competition here
SCAL vs IHHHF Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, IHHHF has a market cap of 9.7B. Regarding current trading prices, SCAL is priced at $0.00, while IHHHF trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas IHHHF's P/E ratio is 15.71. In terms of profitability, SCAL's ROE is +0.07%, compared to IHHHF's ROE of +0.07%. Regarding short-term risk, SCAL is less volatile compared to IHHHF. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check IHHHF's competition here
SCAL vs BDUUF Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, BDUUF has a market cap of 9.5B. Regarding current trading prices, SCAL is priced at $0.00, while BDUUF trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas BDUUF's P/E ratio is 20.00. In terms of profitability, SCAL's ROE is +0.07%, compared to BDUUF's ROE of +0.15%. Regarding short-term risk, SCAL and BDUUF have similar daily volatility (0.00).Check BDUUF's competition here
SCAL vs RMYHY Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, RMYHY has a market cap of 6B. Regarding current trading prices, SCAL is priced at $0.00, while RMYHY trades at $6.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas RMYHY's P/E ratio is 29.77. In terms of profitability, SCAL's ROE is +0.07%, compared to RMYHY's ROE of +0.06%. Regarding short-term risk, SCAL and RMYHY have similar daily volatility (0.00).Check RMYHY's competition here
SCAL vs RMSYF Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, RMSYF has a market cap of 5.7B. Regarding current trading prices, SCAL is priced at $0.00, while RMSYF trades at $25.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas RMSYF's P/E ratio is 357.14. In terms of profitability, SCAL's ROE is +0.07%, compared to RMSYF's ROE of +0.06%. Regarding short-term risk, SCAL and RMSYF have similar daily volatility (0.00).Check RMSYF's competition here
SCAL vs BUHPF Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, BUHPF has a market cap of 4.5B. Regarding current trading prices, SCAL is priced at $0.00, while BUHPF trades at $5.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas BUHPF's P/E ratio is 20.93. In terms of profitability, SCAL's ROE is +0.07%, compared to BUHPF's ROE of +0.26%. Regarding short-term risk, SCAL and BUHPF have similar daily volatility (0.00).Check BUHPF's competition here
SCAL vs ANHGY Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, ANHGY has a market cap of 4B. Regarding current trading prices, SCAL is priced at $0.00, while ANHGY trades at $5.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas ANHGY's P/E ratio is 23.87. In terms of profitability, SCAL's ROE is +0.07%, compared to ANHGY's ROE of N/A. Regarding short-term risk, SCAL and ANHGY have similar daily volatility (0.00).Check ANHGY's competition here
SCAL vs BUGDF Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, BUGDF has a market cap of 3.8B. Regarding current trading prices, SCAL is priced at $0.00, while BUGDF trades at $4.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas BUGDF's P/E ratio is 16.96. In terms of profitability, SCAL's ROE is +0.07%, compared to BUGDF's ROE of +0.26%. Regarding short-term risk, SCAL and BUGDF have similar daily volatility (0.00).Check BUGDF's competition here
SCAL vs MCVEY Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, MCVEY has a market cap of 3.2B. Regarding current trading prices, SCAL is priced at $0.00, while MCVEY trades at $21.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas MCVEY's P/E ratio is 52.54. In terms of profitability, SCAL's ROE is +0.07%, compared to MCVEY's ROE of +0.14%. Regarding short-term risk, SCAL is less volatile compared to MCVEY. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check MCVEY's competition here
SCAL vs RHCGF Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, RHCGF has a market cap of 3.2B. Regarding current trading prices, SCAL is priced at $0.00, while RHCGF trades at $3.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas RHCGF's P/E ratio is -11.11. In terms of profitability, SCAL's ROE is +0.07%, compared to RHCGF's ROE of -0.14%. Regarding short-term risk, SCAL and RHCGF have similar daily volatility (0.00).Check RHCGF's competition here
SCAL vs MCVEF Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, MCVEF has a market cap of 2.7B. Regarding current trading prices, SCAL is priced at $0.00, while MCVEF trades at $18.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas MCVEF's P/E ratio is 34.62. In terms of profitability, SCAL's ROE is +0.07%, compared to MCVEF's ROE of +0.16%. Regarding short-term risk, SCAL is less volatile compared to MCVEF. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check MCVEF's competition here
SCAL vs JXFGF Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, JXFGF has a market cap of 2.7B. Regarding current trading prices, SCAL is priced at $0.00, while JXFGF trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas JXFGF's P/E ratio is -20.00. In terms of profitability, SCAL's ROE is +0.07%, compared to JXFGF's ROE of -0.11%. Regarding short-term risk, SCAL is less volatile compared to JXFGF. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check JXFGF's competition here
SCAL vs EXETF Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, EXETF has a market cap of 1.8B. Regarding current trading prices, SCAL is priced at $0.00, while EXETF trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas EXETF's P/E ratio is 23.22. In terms of profitability, SCAL's ROE is +0.07%, compared to EXETF's ROE of +0.48%. Regarding short-term risk, SCAL is less volatile compared to EXETF. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check EXETF's competition here
SCAL vs LWSCF Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, LWSCF has a market cap of 1.6B. Regarding current trading prices, SCAL is priced at $0.00, while LWSCF trades at $15.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas LWSCF's P/E ratio is 44.91. In terms of profitability, SCAL's ROE is +0.07%, compared to LWSCF's ROE of +0.07%. Regarding short-term risk, SCAL is less volatile compared to LWSCF. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check LWSCF's competition here
SCAL vs RAFLF Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, RAFLF has a market cap of 1.5B. Regarding current trading prices, SCAL is priced at $0.00, while RAFLF trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas RAFLF's P/E ratio is 26.50. In terms of profitability, SCAL's ROE is +0.07%, compared to RAFLF's ROE of +0.06%. Regarding short-term risk, SCAL is less volatile compared to RAFLF. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check RAFLF's competition here
SCAL vs TTALF Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, TTALF has a market cap of 1.4B. Regarding current trading prices, SCAL is priced at $0.00, while TTALF trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas TTALF's P/E ratio is 13.10. In terms of profitability, SCAL's ROE is +0.07%, compared to TTALF's ROE of +0.16%. Regarding short-term risk, SCAL and TTALF have similar daily volatility (0.00).Check TTALF's competition here
SCAL vs RKAGY Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, RKAGY has a market cap of 1.1B. Regarding current trading prices, SCAL is priced at $0.00, while RKAGY trades at $8.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas RKAGY's P/E ratio is 24.73. In terms of profitability, SCAL's ROE is +0.07%, compared to RKAGY's ROE of +0.03%. Regarding short-term risk, SCAL and RKAGY have similar daily volatility (0.00).Check RKAGY's competition here
SCAL vs RYHTY Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, RYHTY has a market cap of 1.1B. Regarding current trading prices, SCAL is priced at $0.00, while RYHTY trades at $6.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas RYHTY's P/E ratio is -4.59. In terms of profitability, SCAL's ROE is +0.07%, compared to RYHTY's ROE of -0.14%. Regarding short-term risk, SCAL and RYHTY have similar daily volatility (0.00).Check RYHTY's competition here
SCAL vs LTGHF Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, LTGHF has a market cap of 1B. Regarding current trading prices, SCAL is priced at $0.00, while LTGHF trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas LTGHF's P/E ratio is -12.02. In terms of profitability, SCAL's ROE is +0.07%, compared to LTGHF's ROE of +8.48%. Regarding short-term risk, SCAL and LTGHF have similar daily volatility (0.00).Check LTGHF's competition here
SCAL vs RHKJF Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, RHKJF has a market cap of 1B. Regarding current trading prices, SCAL is priced at $0.00, while RHKJF trades at $15.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas RHKJF's P/E ratio is 21.55. In terms of profitability, SCAL's ROE is +0.07%, compared to RHKJF's ROE of +0.03%. Regarding short-term risk, SCAL and RHKJF have similar daily volatility (0.00).Check RHKJF's competition here
SCAL vs LTGHY Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, LTGHY has a market cap of 948.1M. Regarding current trading prices, SCAL is priced at $0.00, while LTGHY trades at $2.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas LTGHY's P/E ratio is -10.40. In terms of profitability, SCAL's ROE is +0.07%, compared to LTGHY's ROE of +0.38%. Regarding short-term risk, SCAL is less volatile compared to LTGHY. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check LTGHY's competition here
SCAL vs NWKHY Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, NWKHY has a market cap of 854.5M. Regarding current trading prices, SCAL is priced at $0.00, while NWKHY trades at $7.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas NWKHY's P/E ratio is 10.39. In terms of profitability, SCAL's ROE is +0.07%, compared to NWKHY's ROE of +0.16%. Regarding short-term risk, SCAL and NWKHY have similar daily volatility (0.00).Check NWKHY's competition here
SCAL vs KDGTF Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, KDGTF has a market cap of 675.1M. Regarding current trading prices, SCAL is priced at $0.00, while KDGTF trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas KDGTF's P/E ratio is -1.67. In terms of profitability, SCAL's ROE is +0.07%, compared to KDGTF's ROE of N/A. Regarding short-term risk, SCAL and KDGTF have similar daily volatility (0.00).Check KDGTF's competition here
SCAL vs WHTCF Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, WHTCF has a market cap of 667M. Regarding current trading prices, SCAL is priced at $0.00, while WHTCF trades at $2.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas WHTCF's P/E ratio is -130.55. In terms of profitability, SCAL's ROE is +0.07%, compared to WHTCF's ROE of -0.06%. Regarding short-term risk, SCAL and WHTCF have similar daily volatility (0.00).Check WHTCF's competition here
SCAL vs WFHG Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, WFHG has a market cap of 472.5M. Regarding current trading prices, SCAL is priced at $0.00, while WFHG trades at $7.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas WFHG's P/E ratio is N/A. In terms of profitability, SCAL's ROE is +0.07%, compared to WFHG's ROE of +0.00%. Regarding short-term risk, SCAL and WFHG have similar daily volatility (0.00).Check WFHG's competition here
SCAL vs ORRRY Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, ORRRY has a market cap of 371.5M. Regarding current trading prices, SCAL is priced at $0.00, while ORRRY trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas ORRRY's P/E ratio is -0.33. In terms of profitability, SCAL's ROE is +0.07%, compared to ORRRY's ROE of +7.04%. Regarding short-term risk, SCAL and ORRRY have similar daily volatility (0.00).Check ORRRY's competition here
SCAL vs BTMDW Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, BTMDW has a market cap of 292.9M. Regarding current trading prices, SCAL is priced at $0.00, while BTMDW trades at $1.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas BTMDW's P/E ratio is 0.05. In terms of profitability, SCAL's ROE is +0.07%, compared to BTMDW's ROE of -0.35%. Regarding short-term risk, SCAL is less volatile compared to BTMDW. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check BTMDW's competition here
SCAL vs ORPEF Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, ORPEF has a market cap of 241.9M. Regarding current trading prices, SCAL is priced at $0.00, while ORPEF trades at $1.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas ORPEF's P/E ratio is N/A. In terms of profitability, SCAL's ROE is +0.07%, compared to ORPEF's ROE of -0.13%. Regarding short-term risk, SCAL is less volatile compared to ORPEF. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check ORPEF's competition here
SCAL vs MFCSF Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, MFCSF has a market cap of 219.1M. Regarding current trading prices, SCAL is priced at $0.00, while MFCSF trades at $11.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas MFCSF's P/E ratio is 15.06. In terms of profitability, SCAL's ROE is +0.07%, compared to MFCSF's ROE of +0.27%. Regarding short-term risk, SCAL and MFCSF have similar daily volatility (0.00).Check MFCSF's competition here
SCAL vs MKLNF Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, MKLNF has a market cap of 214.8M. Regarding current trading prices, SCAL is priced at $0.00, while MKLNF trades at $11.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas MKLNF's P/E ratio is 19.23. In terms of profitability, SCAL's ROE is +0.07%, compared to MKLNF's ROE of +0.16%. Regarding short-term risk, SCAL and MKLNF have similar daily volatility (0.00).Check MKLNF's competition here
SCAL vs CHHHF Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, CHHHF has a market cap of 165.6M. Regarding current trading prices, SCAL is priced at $0.00, while CHHHF trades at $2.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas CHHHF's P/E ratio is 8.80. In terms of profitability, SCAL's ROE is +0.07%, compared to CHHHF's ROE of +0.28%. Regarding short-term risk, SCAL and CHHHF have similar daily volatility (0.00).Check CHHHF's competition here
SCAL vs HWAIF Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, HWAIF has a market cap of 155M. Regarding current trading prices, SCAL is priced at $0.00, while HWAIF trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas HWAIF's P/E ratio is -4.80. In terms of profitability, SCAL's ROE is +0.07%, compared to HWAIF's ROE of -0.39%. Regarding short-term risk, SCAL is less volatile compared to HWAIF. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check HWAIF's competition here
SCAL vs COLRF Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, COLRF has a market cap of 123M. Regarding current trading prices, SCAL is priced at $0.00, while COLRF trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas COLRF's P/E ratio is -8.00. In terms of profitability, SCAL's ROE is +0.07%, compared to COLRF's ROE of +0.00%. Regarding short-term risk, SCAL is less volatile compared to COLRF. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check COLRF's competition here
SCAL vs VTIAF Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, VTIAF has a market cap of 108.9M. Regarding current trading prices, SCAL is priced at $0.00, while VTIAF trades at $6.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas VTIAF's P/E ratio is -8.93. In terms of profitability, SCAL's ROE is +0.07%, compared to VTIAF's ROE of -0.71%. Regarding short-term risk, SCAL and VTIAF have similar daily volatility (0.00).Check VTIAF's competition here
SCAL vs TOKIF Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, TOKIF has a market cap of 101.4M. Regarding current trading prices, SCAL is priced at $0.00, while TOKIF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas TOKIF's P/E ratio is -0.57. In terms of profitability, SCAL's ROE is +0.07%, compared to TOKIF's ROE of -0.83%. Regarding short-term risk, SCAL is less volatile compared to TOKIF. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check TOKIF's competition here
SCAL vs NAFS Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, NAFS has a market cap of 59.6M. Regarding current trading prices, SCAL is priced at $0.00, while NAFS trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas NAFS's P/E ratio is N/A. In terms of profitability, SCAL's ROE is +0.07%, compared to NAFS's ROE of +0.31%. Regarding short-term risk, SCAL and NAFS have similar daily volatility (0.00).Check NAFS's competition here
SCAL vs MCIOF Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, MCIOF has a market cap of 54M. Regarding current trading prices, SCAL is priced at $0.00, while MCIOF trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas MCIOF's P/E ratio is -1.22. In terms of profitability, SCAL's ROE is +0.07%, compared to MCIOF's ROE of N/A. Regarding short-term risk, SCAL and MCIOF have similar daily volatility (0.00).Check MCIOF's competition here
SCAL vs ASSF Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, ASSF has a market cap of 45.3M. Regarding current trading prices, SCAL is priced at $0.00, while ASSF trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas ASSF's P/E ratio is -33.33. In terms of profitability, SCAL's ROE is +0.07%, compared to ASSF's ROE of -6.63%. Regarding short-term risk, SCAL and ASSF have similar daily volatility (0.00).Check ASSF's competition here
SCAL vs NVLPF Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, NVLPF has a market cap of 26.2M. Regarding current trading prices, SCAL is priced at $0.00, while NVLPF trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas NVLPF's P/E ratio is 30.00. In terms of profitability, SCAL's ROE is +0.07%, compared to NVLPF's ROE of -0.01%. Regarding short-term risk, SCAL and NVLPF have similar daily volatility (0.00).Check NVLPF's competition here
SCAL vs USNU Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, USNU has a market cap of 22.2M. Regarding current trading prices, SCAL is priced at $0.00, while USNU trades at $1.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas USNU's P/E ratio is -9.41. In terms of profitability, SCAL's ROE is +0.07%, compared to USNU's ROE of -0.71%. Regarding short-term risk, SCAL is less volatile compared to USNU. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check USNU's competition here
SCAL vs HQDA Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, HQDA has a market cap of 18.6M. Regarding current trading prices, SCAL is priced at $0.00, while HQDA trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas HQDA's P/E ratio is N/A. In terms of profitability, SCAL's ROE is +0.07%, compared to HQDA's ROE of -0.06%. Regarding short-term risk, SCAL and HQDA have similar daily volatility (0.00).Check HQDA's competition here
SCAL vs GBCS Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, GBCS has a market cap of 12.6M. Regarding current trading prices, SCAL is priced at $0.00, while GBCS trades at $4.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas GBCS's P/E ratio is -14.64. In terms of profitability, SCAL's ROE is +0.07%, compared to GBCS's ROE of +0.13%. Regarding short-term risk, SCAL is less volatile compared to GBCS. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check GBCS's competition here
SCAL vs EVGRF Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, EVGRF has a market cap of 11.9M. Regarding current trading prices, SCAL is priced at $0.00, while EVGRF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas EVGRF's P/E ratio is N/A. In terms of profitability, SCAL's ROE is +0.07%, compared to EVGRF's ROE of +0.22%. Regarding short-term risk, SCAL is less volatile compared to EVGRF. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check EVGRF's competition here
SCAL vs FPCG Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, FPCG has a market cap of 10.1M. Regarding current trading prices, SCAL is priced at $0.00, while FPCG trades at $1,025.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas FPCG's P/E ratio is 0.09. In terms of profitability, SCAL's ROE is +0.07%, compared to FPCG's ROE of +0.00%. Regarding short-term risk, SCAL and FPCG have similar daily volatility (0.00).Check FPCG's competition here
SCAL vs HLYK Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, HLYK has a market cap of 9.4M. Regarding current trading prices, SCAL is priced at $0.00, while HLYK trades at $3.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas HLYK's P/E ratio is -2.75. In terms of profitability, SCAL's ROE is +0.07%, compared to HLYK's ROE of +0.88%. Regarding short-term risk, SCAL is less volatile compared to HLYK. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check HLYK's competition here
SCAL vs BICX Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, BICX has a market cap of 7.6M. Regarding current trading prices, SCAL is priced at $0.00, while BICX trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas BICX's P/E ratio is -1.25. In terms of profitability, SCAL's ROE is +0.07%, compared to BICX's ROE of +0.41%. Regarding short-term risk, SCAL and BICX have similar daily volatility (0.00).Check BICX's competition here
SCAL vs RVLWF Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, RVLWF has a market cap of 5.4M. Regarding current trading prices, SCAL is priced at $0.00, while RVLWF trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas RVLWF's P/E ratio is -0.30. In terms of profitability, SCAL's ROE is +0.07%, compared to RVLWF's ROE of +3.95%. Regarding short-term risk, SCAL and RVLWF have similar daily volatility (0.00).Check RVLWF's competition here
SCAL vs VLXC Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, VLXC has a market cap of 3.9M. Regarding current trading prices, SCAL is priced at $0.00, while VLXC trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas VLXC's P/E ratio is -4.00. In terms of profitability, SCAL's ROE is +0.07%, compared to VLXC's ROE of +0.74%. Regarding short-term risk, SCAL is less volatile compared to VLXC. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check VLXC's competition here
SCAL vs XCRT Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, XCRT has a market cap of 3.5M. Regarding current trading prices, SCAL is priced at $0.00, while XCRT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas XCRT's P/E ratio is N/A. In terms of profitability, SCAL's ROE is +0.07%, compared to XCRT's ROE of +0.26%. Regarding short-term risk, SCAL is less volatile compared to XCRT. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check XCRT's competition here
SCAL vs RHEP Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, RHEP has a market cap of 3.1M. Regarding current trading prices, SCAL is priced at $0.00, while RHEP trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas RHEP's P/E ratio is -7.94. In terms of profitability, SCAL's ROE is +0.07%, compared to RHEP's ROE of -0.04%. Regarding short-term risk, SCAL is less volatile compared to RHEP. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check RHEP's competition here
SCAL vs NUMIF Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, NUMIF has a market cap of 2.9M. Regarding current trading prices, SCAL is priced at $0.00, while NUMIF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas NUMIF's P/E ratio is -0.30. In terms of profitability, SCAL's ROE is +0.07%, compared to NUMIF's ROE of +11.51%. Regarding short-term risk, SCAL is less volatile compared to NUMIF. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check NUMIF's competition here
SCAL vs EPWCF Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, EPWCF has a market cap of 2.5M. Regarding current trading prices, SCAL is priced at $0.00, while EPWCF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas EPWCF's P/E ratio is -0.00. In terms of profitability, SCAL's ROE is +0.07%, compared to EPWCF's ROE of +0.00%. Regarding short-term risk, SCAL is less volatile compared to EPWCF. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check EPWCF's competition here
SCAL vs NRPR Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, NRPR has a market cap of 2.1M. Regarding current trading prices, SCAL is priced at $0.00, while NRPR trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas NRPR's P/E ratio is -0.03. In terms of profitability, SCAL's ROE is +0.07%, compared to NRPR's ROE of N/A. Regarding short-term risk, SCAL and NRPR have similar daily volatility (0.00).Check NRPR's competition here
SCAL vs KJFI Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, KJFI has a market cap of 1.6M. Regarding current trading prices, SCAL is priced at $0.00, while KJFI trades at $0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas KJFI's P/E ratio is -0.06. In terms of profitability, SCAL's ROE is +0.07%, compared to KJFI's ROE of +0.00%. Regarding short-term risk, SCAL and KJFI have similar daily volatility (0.00).Check KJFI's competition here
SCAL vs GRST Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, GRST has a market cap of 1.5M. Regarding current trading prices, SCAL is priced at $0.00, while GRST trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas GRST's P/E ratio is N/A. In terms of profitability, SCAL's ROE is +0.07%, compared to GRST's ROE of +0.17%. Regarding short-term risk, SCAL and GRST have similar daily volatility (0.00).Check GRST's competition here
SCAL vs SMAS Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, SMAS has a market cap of 1.5M. Regarding current trading prices, SCAL is priced at $0.00, while SMAS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas SMAS's P/E ratio is N/A. In terms of profitability, SCAL's ROE is +0.07%, compared to SMAS's ROE of N/A. Regarding short-term risk, SCAL is less volatile compared to SMAS. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check SMAS's competition here
SCAL vs MDGP Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, MDGP has a market cap of 1.5M. Regarding current trading prices, SCAL is priced at $0.00, while MDGP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas MDGP's P/E ratio is N/A. In terms of profitability, SCAL's ROE is +0.07%, compared to MDGP's ROE of -2.19%. Regarding short-term risk, SCAL and MDGP have similar daily volatility (0.00).Check MDGP's competition here
SCAL vs MAHN Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, MAHN has a market cap of 1.2M. Regarding current trading prices, SCAL is priced at $0.00, while MAHN trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas MAHN's P/E ratio is 50.00. In terms of profitability, SCAL's ROE is +0.07%, compared to MAHN's ROE of N/A. Regarding short-term risk, SCAL and MAHN have similar daily volatility (0.00).Check MAHN's competition here
SCAL vs NOVC Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, NOVC has a market cap of 1.2M. Regarding current trading prices, SCAL is priced at $0.00, while NOVC trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas NOVC's P/E ratio is -0.20. In terms of profitability, SCAL's ROE is +0.07%, compared to NOVC's ROE of +0.12%. Regarding short-term risk, SCAL and NOVC have similar daily volatility (0.00).Check NOVC's competition here
SCAL vs DPAT Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, DPAT has a market cap of 1.1M. Regarding current trading prices, SCAL is priced at $0.00, while DPAT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas DPAT's P/E ratio is -2.25. In terms of profitability, SCAL's ROE is +0.07%, compared to DPAT's ROE of +0.45%. Regarding short-term risk, SCAL and DPAT have similar daily volatility (0.00).Check DPAT's competition here
SCAL vs PHMB Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, PHMB has a market cap of 1.1M. Regarding current trading prices, SCAL is priced at $0.00, while PHMB trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas PHMB's P/E ratio is N/A. In terms of profitability, SCAL's ROE is +0.07%, compared to PHMB's ROE of N/A. Regarding short-term risk, SCAL is less volatile compared to PHMB. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check PHMB's competition here
SCAL vs GNOW Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, GNOW has a market cap of 859.7K. Regarding current trading prices, SCAL is priced at $0.00, while GNOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas GNOW's P/E ratio is -0.01. In terms of profitability, SCAL's ROE is +0.07%, compared to GNOW's ROE of -12.49%. Regarding short-term risk, SCAL and GNOW have similar daily volatility (0.00).Check GNOW's competition here
SCAL vs JRSS Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, JRSS has a market cap of 837.5K. Regarding current trading prices, SCAL is priced at $0.00, while JRSS trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas JRSS's P/E ratio is -0.10. In terms of profitability, SCAL's ROE is +0.07%, compared to JRSS's ROE of +0.89%. Regarding short-term risk, SCAL is less volatile compared to JRSS. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check JRSS's competition here
SCAL vs MSITF Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, MSITF has a market cap of 480K. Regarding current trading prices, SCAL is priced at $0.00, while MSITF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas MSITF's P/E ratio is -0.10. In terms of profitability, SCAL's ROE is +0.07%, compared to MSITF's ROE of N/A. Regarding short-term risk, SCAL is less volatile compared to MSITF. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check MSITF's competition here
SCAL vs ARPC Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, ARPC has a market cap of 336.6K. Regarding current trading prices, SCAL is priced at $0.00, while ARPC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas ARPC's P/E ratio is N/A. In terms of profitability, SCAL's ROE is +0.07%, compared to ARPC's ROE of +3.10%. Regarding short-term risk, SCAL is less volatile compared to ARPC. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check ARPC's competition here
SCAL vs NXGT Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, NXGT has a market cap of 292.2K. Regarding current trading prices, SCAL is priced at $0.00, while NXGT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas NXGT's P/E ratio is N/A. In terms of profitability, SCAL's ROE is +0.07%, compared to NXGT's ROE of +0.04%. Regarding short-term risk, SCAL and NXGT have similar daily volatility (0.00).Check NXGT's competition here
SCAL vs BNYN Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, BNYN has a market cap of 286K. Regarding current trading prices, SCAL is priced at $0.00, while BNYN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas BNYN's P/E ratio is N/A. In terms of profitability, SCAL's ROE is +0.07%, compared to BNYN's ROE of -14.10%. Regarding short-term risk, SCAL is less volatile compared to BNYN. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check BNYN's competition here
SCAL vs SETO Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, SETO has a market cap of 234.5K. Regarding current trading prices, SCAL is priced at $0.00, while SETO trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas SETO's P/E ratio is -1.88. In terms of profitability, SCAL's ROE is +0.07%, compared to SETO's ROE of -123.80%. Regarding short-term risk, SCAL is less volatile compared to SETO. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check SETO's competition here
SCAL vs FCHS Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, FCHS has a market cap of 131.8K. Regarding current trading prices, SCAL is priced at $0.00, while FCHS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas FCHS's P/E ratio is -0.04. In terms of profitability, SCAL's ROE is +0.07%, compared to FCHS's ROE of +0.20%. Regarding short-term risk, SCAL and FCHS have similar daily volatility (0.00).Check FCHS's competition here
SCAL vs TPIA Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, TPIA has a market cap of 113.8K. Regarding current trading prices, SCAL is priced at $0.00, while TPIA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas TPIA's P/E ratio is -0.15. In terms of profitability, SCAL's ROE is +0.07%, compared to TPIA's ROE of +0.55%. Regarding short-term risk, SCAL is less volatile compared to TPIA. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check TPIA's competition here
SCAL vs AMBD Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, AMBD has a market cap of 85.6K. Regarding current trading prices, SCAL is priced at $0.00, while AMBD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas AMBD's P/E ratio is N/A. In terms of profitability, SCAL's ROE is +0.07%, compared to AMBD's ROE of +1.11%. Regarding short-term risk, SCAL is less volatile compared to AMBD. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check AMBD's competition here
SCAL vs JNHMF Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, JNHMF has a market cap of 69.7K. Regarding current trading prices, SCAL is priced at $0.00, while JNHMF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas JNHMF's P/E ratio is -0.01. In terms of profitability, SCAL's ROE is +0.07%, compared to JNHMF's ROE of -3.60%. Regarding short-term risk, SCAL is less volatile compared to JNHMF. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check JNHMF's competition here
SCAL vs NMHLY Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, NMHLY has a market cap of 41.7K. Regarding current trading prices, SCAL is priced at $0.00, while NMHLY trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas NMHLY's P/E ratio is 0.02. In terms of profitability, SCAL's ROE is +0.07%, compared to NMHLY's ROE of N/A. Regarding short-term risk, SCAL and NMHLY have similar daily volatility (0.00).Check NMHLY's competition here
SCAL vs CLRD Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, CLRD has a market cap of 28.8K. Regarding current trading prices, SCAL is priced at $0.00, while CLRD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas CLRD's P/E ratio is -0.01. In terms of profitability, SCAL's ROE is +0.07%, compared to CLRD's ROE of +0.38%. Regarding short-term risk, SCAL is less volatile compared to CLRD. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check CLRD's competition here
SCAL vs MSGP Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, MSGP has a market cap of 26K. Regarding current trading prices, SCAL is priced at $0.00, while MSGP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas MSGP's P/E ratio is N/A. In terms of profitability, SCAL's ROE is +0.07%, compared to MSGP's ROE of +0.27%. Regarding short-term risk, SCAL is less volatile compared to MSGP. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check MSGP's competition here
SCAL vs HSMD Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, HSMD has a market cap of 18.4K. Regarding current trading prices, SCAL is priced at $0.00, while HSMD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas HSMD's P/E ratio is -0.01. In terms of profitability, SCAL's ROE is +0.07%, compared to HSMD's ROE of -0.04%. Regarding short-term risk, SCAL and HSMD have similar daily volatility (0.00).Check HSMD's competition here
SCAL vs CEVE Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, CEVE has a market cap of 17.1K. Regarding current trading prices, SCAL is priced at $0.00, while CEVE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas CEVE's P/E ratio is N/A. In terms of profitability, SCAL's ROE is +0.07%, compared to CEVE's ROE of +2.26%. Regarding short-term risk, SCAL and CEVE have similar daily volatility (0.00).Check CEVE's competition here
SCAL vs PRMD Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, PRMD has a market cap of 12.9K. Regarding current trading prices, SCAL is priced at $0.00, while PRMD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas PRMD's P/E ratio is N/A. In terms of profitability, SCAL's ROE is +0.07%, compared to PRMD's ROE of +0.73%. Regarding short-term risk, SCAL is less volatile compared to PRMD. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check PRMD's competition here
SCAL vs GENN Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, GENN has a market cap of 12.1K. Regarding current trading prices, SCAL is priced at $0.00, while GENN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas GENN's P/E ratio is -0.01. In terms of profitability, SCAL's ROE is +0.07%, compared to GENN's ROE of +0.07%. Regarding short-term risk, SCAL is less volatile compared to GENN. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check GENN's competition here
SCAL vs CHCR Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, CHCR has a market cap of 12K. Regarding current trading prices, SCAL is priced at $0.00, while CHCR trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas CHCR's P/E ratio is -0.00. In terms of profitability, SCAL's ROE is +0.07%, compared to CHCR's ROE of N/A. Regarding short-term risk, SCAL and CHCR have similar daily volatility (0.00).Check CHCR's competition here
SCAL vs ACGI Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, ACGI has a market cap of 10.5K. Regarding current trading prices, SCAL is priced at $0.00, while ACGI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas ACGI's P/E ratio is N/A. In terms of profitability, SCAL's ROE is +0.07%, compared to ACGI's ROE of +1.11%. Regarding short-term risk, SCAL is less volatile compared to ACGI. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check ACGI's competition here
SCAL vs WEQL Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, WEQL has a market cap of 7.2K. Regarding current trading prices, SCAL is priced at $0.00, while WEQL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas WEQL's P/E ratio is N/A. In terms of profitability, SCAL's ROE is +0.07%, compared to WEQL's ROE of +0.21%. Regarding short-term risk, SCAL is less volatile compared to WEQL. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check WEQL's competition here
SCAL vs PAOG Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, PAOG has a market cap of 5K. Regarding current trading prices, SCAL is priced at $0.00, while PAOG trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas PAOG's P/E ratio is N/A. In terms of profitability, SCAL's ROE is +0.07%, compared to PAOG's ROE of -0.20%. Regarding short-term risk, SCAL and PAOG have similar daily volatility (0.00).Check PAOG's competition here
SCAL vs SLHGF Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, SLHGF has a market cap of 4K. Regarding current trading prices, SCAL is priced at $0.00, while SLHGF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas SLHGF's P/E ratio is N/A. In terms of profitability, SCAL's ROE is +0.07%, compared to SLHGF's ROE of -0.42%. Regarding short-term risk, SCAL is less volatile compared to SLHGF. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check SLHGF's competition here
SCAL vs SLHPF Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, SLHPF has a market cap of 3.9K. Regarding current trading prices, SCAL is priced at $0.00, while SLHPF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas SLHPF's P/E ratio is N/A. In terms of profitability, SCAL's ROE is +0.07%, compared to SLHPF's ROE of -0.42%. Regarding short-term risk, SCAL is less volatile compared to SLHPF. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check SLHPF's competition here
SCAL vs ERUC Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, ERUC has a market cap of 3.9K. Regarding current trading prices, SCAL is priced at $0.00, while ERUC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas ERUC's P/E ratio is N/A. In terms of profitability, SCAL's ROE is +0.07%, compared to ERUC's ROE of N/A. Regarding short-term risk, SCAL and ERUC have similar daily volatility (0.00).Check ERUC's competition here
SCAL vs BBAL Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, BBAL has a market cap of 3.4K. Regarding current trading prices, SCAL is priced at $0.00, while BBAL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas BBAL's P/E ratio is N/A. In terms of profitability, SCAL's ROE is +0.07%, compared to BBAL's ROE of +0.45%. Regarding short-term risk, SCAL and BBAL have similar daily volatility (0.00).Check BBAL's competition here
SCAL vs DRWN Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, DRWN has a market cap of 2.4K. Regarding current trading prices, SCAL is priced at $0.00, while DRWN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas DRWN's P/E ratio is N/A. In terms of profitability, SCAL's ROE is +0.07%, compared to DRWN's ROE of -0.01%. Regarding short-term risk, SCAL and DRWN have similar daily volatility (0.00).Check DRWN's competition here
SCAL vs NMMCF Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, NMMCF has a market cap of 2.1K. Regarding current trading prices, SCAL is priced at $0.00, while NMMCF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas NMMCF's P/E ratio is N/A. In terms of profitability, SCAL's ROE is +0.07%, compared to NMMCF's ROE of +0.21%. Regarding short-term risk, SCAL is less volatile compared to NMMCF. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check NMMCF's competition here
SCAL vs PPRG Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, PPRG has a market cap of 1.6K. Regarding current trading prices, SCAL is priced at $0.00, while PPRG trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas PPRG's P/E ratio is N/A. In terms of profitability, SCAL's ROE is +0.07%, compared to PPRG's ROE of -0.58%. Regarding short-term risk, SCAL and PPRG have similar daily volatility (0.00).Check PPRG's competition here
SCAL vs KONEF Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, KONEF has a market cap of 1.6K. Regarding current trading prices, SCAL is priced at $0.00, while KONEF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas KONEF's P/E ratio is N/A. In terms of profitability, SCAL's ROE is +0.07%, compared to KONEF's ROE of -6.56%. Regarding short-term risk, SCAL is less volatile compared to KONEF. This indicates potentially lower risk in terms of short-term price fluctuations for SCAL.Check KONEF's competition here
SCAL vs OHAQ Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, OHAQ has a market cap of 1.4K. Regarding current trading prices, SCAL is priced at $0.00, while OHAQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas OHAQ's P/E ratio is 0.01. In terms of profitability, SCAL's ROE is +0.07%, compared to OHAQ's ROE of +0.09%. Regarding short-term risk, SCAL and OHAQ have similar daily volatility (0.00).Check OHAQ's competition here
SCAL vs BNKL Comparison April 2026
SCAL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCAL stands at 17.4K. In comparison, BNKL has a market cap of 1.2K. Regarding current trading prices, SCAL is priced at $0.00, while BNKL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCAL currently has a P/E ratio of 0.04, whereas BNKL's P/E ratio is N/A. In terms of profitability, SCAL's ROE is +0.07%, compared to BNKL's ROE of -7.69%. Regarding short-term risk, SCAL and BNKL have similar daily volatility (0.00).Check BNKL's competition here